Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.53
AMAG's Cash-to-Debt is ranked lower than
86% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 59.90 vs. AMAG: 0.53 )
Ranked among companies with meaningful Cash-to-Debt only.
AMAG' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.29  Med: No Debt Max: No Debt
Current: 0.53
Equity-to-Asset 0.38
AMAG's Equity-to-Asset is ranked lower than
79% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. AMAG: 0.38 )
Ranked among companies with meaningful Equity-to-Asset only.
AMAG' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.33  Med: 0.72 Max: 0.98
Current: 0.38
0.33
0.98
Interest Coverage 1.08
AMAG's Interest Coverage is ranked lower than
99% of the 484 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. AMAG: 1.08 )
Ranked among companies with meaningful Interest Coverage only.
AMAG' s Interest Coverage Range Over the Past 10 Years
Min: 1.08  Med: No Debt Max: No Debt
Current: 1.08
Piotroski F-Score: 4
Altman Z-Score: 0.66
Beneish M-Score: -2.94
WACC vs ROIC
4.59%
5.09%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 14.82
AMAG's Operating Margin % is ranked higher than
84% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -88.13 vs. AMAG: 14.82 )
Ranked among companies with meaningful Operating Margin % only.
AMAG' s Operating Margin % Range Over the Past 10 Years
Min: -4107.64  Med: -72.84 Max: 26.59
Current: 14.82
-4107.64
26.59
Net Margin % -0.47
AMAG's Net Margin % is ranked higher than
70% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. AMAG: -0.47 )
Ranked among companies with meaningful Net Margin % only.
AMAG' s Net Margin % Range Over the Past 10 Years
Min: -3696.96  Med: -71.06 Max: 109.19
Current: -0.47
-3696.96
109.19
ROE % -0.27
AMAG's ROE % is ranked higher than
75% of the 874 Companies
in the Global Biotechnology industry.

( Industry Median: -34.32 vs. AMAG: -0.27 )
Ranked among companies with meaningful ROE % only.
AMAG' s ROE % Range Over the Past 10 Years
Min: -52.39  Med: -15.27 Max: 42.96
Current: -0.27
-52.39
42.96
ROA % -0.10
AMAG's ROA % is ranked higher than
77% of the 972 Companies
in the Global Biotechnology industry.

( Industry Median: -30.23 vs. AMAG: -0.10 )
Ranked among companies with meaningful ROA % only.
AMAG' s ROA % Range Over the Past 10 Years
Min: -44.82  Med: -13.1 Max: 16.42
Current: -0.1
-44.82
16.42
ROC (Joel Greenblatt) % 288.57
AMAG's ROC (Joel Greenblatt) % is ranked higher than
97% of the 925 Companies
in the Global Biotechnology industry.

( Industry Median: -407.53 vs. AMAG: 288.57 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
AMAG' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1009.91  Med: -510.9 Max: 475.79
Current: 288.57
-1009.91
475.79
3-Year Revenue Growth Rate 60.80
AMAG's 3-Year Revenue Growth Rate is ranked higher than
92% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. AMAG: 60.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
AMAG' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -31  Med: 19.5 Max: 193.8
Current: 60.8
-31
193.8
3-Year EPS without NRI Growth Rate -45.80
AMAG's 3-Year EPS without NRI Growth Rate is ranked lower than
86% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: -3.10 vs. AMAG: -45.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
AMAG' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -51.7  Med: -2.4 Max: 78.1
Current: -45.8
-51.7
78.1
GuruFocus has detected 3 Warning Signs with AMAG Pharmaceuticals Inc $AMAG.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» AMAG's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

AMAG Guru Trades in Q1 2016

Paul Tudor Jones 286,200 sh (New)
Jim Simons Sold Out
Scott Black Sold Out
Joel Greenblatt 204,184 sh (-5.67%)
» More
Q2 2016

AMAG Guru Trades in Q2 2016

Steven Cohen 446,300 sh (New)
Joel Greenblatt 411,912 sh (+101.74%)
Paul Tudor Jones 375,500 sh (+31.20%)
» More
Q3 2016

AMAG Guru Trades in Q3 2016

Joel Greenblatt 507,809 sh (+23.28%)
Paul Tudor Jones Sold Out
Steven Cohen Sold Out
» More
Q4 2016

AMAG Guru Trades in Q4 2016

Paul Tudor Jones 11,200 sh (New)
Jim Simons 513,500 sh (New)
Joel Greenblatt 600,584 sh (+18.27%)
» More
» Details

Insider Trades

Latest Guru Trades with AMAG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:ZIOP, NAS:VSAR, NAS:FOLD, NAS:INSY, OTCPK:SXMDF, NAS:ANIK, NAS:PGNX, NAS:CLLS, NAS:INSM, NAS:AMRN, OTCPK:GNFTF, OTCPK:BPMUF, NAS:ANIP, OTCPK:PHMMF, NAS:AMRI, NAS:XLRN, NAS:ARDX, NAS:CORT, NAS:VNDA, OTCPK:IPHYF » details
Traded in other countries:AMU.Germany,
AMAG Pharmaceuticals Inc is a specialty pharmaceutical company with a focus on maternal health, anemia and cancer supportive care. The Company markets Makena; Feraheme, Injection for Intravenous ("IV") use; and MuGard, Mucoadhesive Oral Wound Rinse.

AMAG Pharmaceuticals Inc is a Delaware corporation was founded in 1981. The Company is a specialty pharmaceutical company that markets Feraheme Injection for Intravenous, or IV, use to treat iron deficiency anemia, or IDA, and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucositis. The Company sells Feraheme to authorized wholesalers and specialty distributors who, in turn, sells Feraheme to healthcare providers who administer Feraheme within hospitals, hematology and oncology centers and nephrology clinics. In addition, it also outsources a number of its product supply chain services to ICS, its third-party logistics provider, including services related to warehousing and inventory management, distribution, chargeback processing, accounts receivable management and customer service call center management. The Company is subject to additional federal, state and foreign healthcare regulation, which includes but is not limited to, the Federal False Claims Act, the Federal Anti-Kickback Statute, the Foreign Corrupt Practices Act, and their state analogues, and similar laws in countries outside of the U.S.

Top Ranked Articles about AMAG Pharmaceuticals Inc

Steven Cohen Buys AMAG Pharmaceuticals Company focuses on development of regenerative medicine
On July 25, Steven Cohen (Trades, Portfolio) of Point72 Asset Management gained a new holding with AMAG Pharmaceuticals Inc. (NASDAQ:AMAG). Read more...

Ratios

vs
industry
vs
history
Forward PE Ratio 3.81
AMAG's Forward PE Ratio is ranked higher than
97% of the 75 Companies
in the Global Biotechnology industry.

( Industry Median: 19.72 vs. AMAG: 3.81 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
Price-to-Owner-Earnings 4.99
AMAG's Price-to-Owner-Earnings is ranked higher than
85% of the 143 Companies
in the Global Biotechnology industry.

( Industry Median: 29.18 vs. AMAG: 4.99 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
AMAG' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 4.58  Med: 11.26 Max: 23.22
Current: 4.99
4.58
23.22
PB Ratio 0.85
AMAG's PB Ratio is ranked higher than
92% of the 1106 Companies
in the Global Biotechnology industry.

( Industry Median: 3.65 vs. AMAG: 0.85 )
Ranked among companies with meaningful PB Ratio only.
AMAG' s PB Ratio Range Over the Past 10 Years
Min: 0.68  Med: 2.49 Max: 18.97
Current: 0.85
0.68
18.97
PS Ratio 1.59
AMAG's PS Ratio is ranked higher than
91% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: 12.50 vs. AMAG: 1.59 )
Ranked among companies with meaningful PS Ratio only.
AMAG' s PS Ratio Range Over the Past 10 Years
Min: 1.5  Med: 7.09 Max: 505.93
Current: 1.59
1.5
505.93
Price-to-Free-Cash-Flow 3.52
AMAG's Price-to-Free-Cash-Flow is ranked higher than
91% of the 140 Companies
in the Global Biotechnology industry.

( Industry Median: 22.44 vs. AMAG: 3.52 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
AMAG' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 3.34  Med: 24.28 Max: 1335.26
Current: 3.52
3.34
1335.26
Price-to-Operating-Cash-Flow 3.44
AMAG's Price-to-Operating-Cash-Flow is ranked higher than
93% of the 204 Companies
in the Global Biotechnology industry.

( Industry Median: 21.56 vs. AMAG: 3.44 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
AMAG' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 3.26  Med: 24.17 Max: 1268.5
Current: 3.44
3.26
1268.5
EV-to-EBIT 15.78
AMAG's EV-to-EBIT is ranked higher than
55% of the 284 Companies
in the Global Biotechnology industry.

( Industry Median: 19.01 vs. AMAG: 15.78 )
Ranked among companies with meaningful EV-to-EBIT only.
AMAG' s EV-to-EBIT Range Over the Past 10 Years
Min: -602.3  Med: -5.8 Max: 87.5
Current: 15.78
-602.3
87.5
EV-to-EBITDA 7.11
AMAG's EV-to-EBITDA is ranked higher than
69% of the 307 Companies
in the Global Biotechnology industry.

( Industry Median: 19.22 vs. AMAG: 7.11 )
Ranked among companies with meaningful EV-to-EBITDA only.
AMAG' s EV-to-EBITDA Range Over the Past 10 Years
Min: -148.3  Med: -5.8 Max: 367.1
Current: 7.11
-148.3
367.1
Current Ratio 2.30
AMAG's Current Ratio is ranked lower than
71% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. AMAG: 2.30 )
Ranked among companies with meaningful Current Ratio only.
AMAG' s Current Ratio Range Over the Past 10 Years
Min: 1.65  Med: 6.77 Max: 36.2
Current: 2.3
1.65
36.2
Quick Ratio 2.18
AMAG's Quick Ratio is ranked lower than
68% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: 3.91 vs. AMAG: 2.18 )
Ranked among companies with meaningful Quick Ratio only.
AMAG' s Quick Ratio Range Over the Past 10 Years
Min: 1.4  Med: 6.32 Max: 36.15
Current: 2.18
1.4
36.15
Days Inventory 123.42
AMAG's Days Inventory is ranked higher than
51% of the 439 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. AMAG: 123.42 )
Ranked among companies with meaningful Days Inventory only.
AMAG' s Days Inventory Range Over the Past 10 Years
Min: 121.63  Med: 441.37 Max: 1713.48
Current: 123.42
121.63
1713.48
Days Sales Outstanding 63.37
AMAG's Days Sales Outstanding is ranked lower than
51% of the 592 Companies
in the Global Biotechnology industry.

( Industry Median: 62.87 vs. AMAG: 63.37 )
Ranked among companies with meaningful Days Sales Outstanding only.
AMAG' s Days Sales Outstanding Range Over the Past 10 Years
Min: 27.4  Med: 49.36 Max: 581.14
Current: 63.37
27.4
581.14
Days Payable 11.50
AMAG's Days Payable is ranked lower than
85% of the 396 Companies
in the Global Biotechnology industry.

( Industry Median: 57.94 vs. AMAG: 11.50 )
Ranked among companies with meaningful Days Payable only.
AMAG' s Days Payable Range Over the Past 10 Years
Min: 11.5  Med: 130.3 Max: 2881.25
Current: 11.5
11.5
2881.25

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -16.30
AMAG's 3-Year Average Share Buyback Ratio is ranked lower than
62% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. AMAG: -16.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AMAG' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -28.7  Med: -7.6 Max: 0.7
Current: -16.3
-28.7
0.7

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.56
AMAG's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
94% of the 174 Companies
in the Global Biotechnology industry.

( Industry Median: 3.31 vs. AMAG: 0.56 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
AMAG' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.56  Med: 1.3 Max: 9.7
Current: 0.56
0.56
9.7
Price-to-Median-PS-Value 0.22
AMAG's Price-to-Median-PS-Value is ranked higher than
92% of the 765 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. AMAG: 0.22 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
AMAG' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.22  Med: 1.12 Max: 50.53
Current: 0.22
0.22
50.53
Earnings Yield (Greenblatt) % 6.38
AMAG's Earnings Yield (Greenblatt) % is ranked higher than
89% of the 1203 Companies
in the Global Biotechnology industry.

( Industry Median: -9.03 vs. AMAG: 6.38 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AMAG' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.1  Med: 4.65 Max: 6.8
Current: 6.38
1.1
6.8

More Statistics

Revenue (TTM) (Mil) $532.1
EPS (TTM) $ -0.11
Beta0.79
Short Percentage of Float34.01%
52-Week Range $17.92 - 36.83
Shares Outstanding (Mil)34.34

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 646 565 581
EPS ($) 6.12 3.52 3.06
EPS without NRI ($) 6.12 3.52 3.06
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for NAS:AMAG

Headlines

Articles On GuruFocus.com
Steven Cohen Increases Position in Dynavax Oct 07 2016 
Steven Cohen Buys AMAG Pharmaceuticals Jul 29 2016 
10 Biotech and Specialty Pharma Bargains: Do You Have the Guts to Speculate? Jul 01 2016 
AMAG Pharmaceuticals Inc. (AMAG) EVP, CFO David Arkowitz sells 2,705 Shares Feb 28 2011 
AMAG Pharmaceuticals Inc. Reports Operating Results (10-Q) May 06 2010 
AMAG Pharmaceuticals Inc. (AMAG) President and CEO Brian Jg Pereira sells 230,011 Shares Nov 12 2009 
AMAG Pharmaceuticals Inc. (AMAG) CFO and Chief Business Officer David Arkowitz sells 4,459 Shares Nov 12 2009 
AMAG Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 05 2009 
AMAG Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 05 2009 
AMAG Pharmaceuticals Inc. (AMAG) President and CEO Brian Jg Pereira sells 5,000 Shares Aug 05 2009 

More From Other Websites
AMAG PHARMACEUTICALS INC. Financials Feb 24 2017
AMAG Pharmaceuticals, Inc. -- Moody's revises outlook on AMAG to stable, affirms B2 CFR Feb 21 2017
AMAG PHARMACEUTICALS INC. Files SEC form 10-K, Annual Report Feb 21 2017
AMAG Pharmaceuticals, Inc. :AMAG-US: Earnings Analysis: 2016 By the Numbers : February 16, 2017 Feb 16 2017
AMAG Pharmaceuticals Inks $60M Drug Deal Feb 16 2017
AMAG Pharmaceuticals, Inc. :AMAG-US: Earnings Analysis: Q4, 2016 By the Numbers : February 15, 2017 Feb 15 2017
AMAG Pharma (AMAG) Incurs Loss in Q4, Revenues Lag Estimates Feb 15 2017
Edited Transcript of AMAG earnings conference call or presentation 14-Feb-17 1:00pm GMT Feb 14 2017
Biotech Premarket Movers: Pacific Biosciences of California, AMAG, Global Blood Therapeutics Feb 14 2017
AMAG Pharmaceuticals Inc Earnings Call scheduled for 8:00 am ET today Feb 14 2017
AMAG Pharmaceuticals reports 4Q loss Feb 14 2017
AMAG Pharmaceuticals reports 4Q loss Feb 14 2017
AMAG PHARMACEUTICALS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Results of... Feb 14 2017
Q4 2016 AMAG Pharmaceuticals Inc Earnings Release - Before Market Open Feb 14 2017
AMAG Reports Fourth Quarter and Full Year 2016 Financial Results Feb 14 2017
AMAG and Endoceutics Enter Into an Exclusive U.S. License Agreement for Intrarosa™ (Prasterone) Feb 14 2017
AMAG Pharmaceuticals to Present at Upcoming Investor Conference Feb 09 2017
AMAG Pharmaceuticals to Host Fourth Quarter and Full Year 2016 Financial Results Conference Call and... Feb 07 2017
AMAG PHARMACEUTICALS INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets,... Feb 03 2017
AMAG Down Despite Positive Data on Makena Auto-Injector Feb 03 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)